Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01740258 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab Beyond Progression (BBP)
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT01740258 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 68 participants.
The verdict
NCT01740258, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
Studies which have separately studied bevacizumab for recurrent gliomas and bevacizumab for newly-diagnosed glioma have shown good results and the regimens have been well-tolerated by patients. This study seeks to investigate the use of bevacizumab with the standard therapy (radiation therapy and temozolomide) in newly diagnosed patients, followed by bevacizumab and temozolomide with the continuation of bevacizumab following progression. Two critical questions remain- the role of bevacizumab maintenance and bevacizumab at the time of progression in a patient previously treated with bevacizumab at the time of initial diagnosis.
Interventions
- DRUG Bevacizumab
- RADIATION Radiation Therapy
- DRUG Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2013-01 |
| Est. Completion | 2019-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01740258
The ClinicalTrials.gov registry entry for NCT01740258 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01740258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01740258 about?
NCT01740258 is a clinical study titled "Bevacizumab Beyond Progression (BBP)". Studies which have separately studied bevacizumab for recurrent gliomas and bevacizumab for newly-diagnosed glioma have shown good results and the regimens have been well-tolerated by patients. This study seeks to investigate the use of bevacizumab with the standard therapy (radiation therapy and te...
What is the current status of trial NCT01740258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2013-01. Estimated completion is 2019-11-14.
What interventions are being tested in trial NCT01740258?
The interventions under investigation include: Bevacizumab (DRUG), Radiation Therapy (RADIATION), Temozolomide (DRUG).
Who is sponsoring clinical trial NCT01740258?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.